KalVista Pharmaceuticals Inc

Venrock sells 5 M KalVista shares for $95 M, boosting cash and boosting clinical momentum for its mTNBC ADC while leaving investors to watch valuation and regulatory moves.

KalVista insider sale: VHCP3 sells 5.1 M shares, yet CEO & execs hold strong, reflecting routine portfolio moves amid solid EKTERLY approval and growth prospects. Click to see what it means for investors.

CEO Palleiko Benjamin L. buys 15,625 KalVista shares, hinting confidence as the company nears key protease‑inhibitor milestones. Explore the impact on investors.

KalVista’s chief development officer buys 1,774 shares, signaling confidence before EKTERLY’s AACC data—insider activity, social‑media buzz, and a $758 M market cap reveal.

KalVista insider buying signals CEO confidence in its biotech pipeline – a cautious, long‑term vote that may boost investor optimism.

KalVista CEO’s new share purchase signals confidence in EKTERLY and a promising oral protease‑inhibitor pipeline, hinting at future upside.